Inmune Bio, Inc. — Director's Dealing 2019

Nov 27, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Inmune Bio, Inc. (INMB)
CIK: 0001711754
Period of Report: 2019-11-25

Reporting Person: Juda Scott (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-11-25	Option	$3.91	A	108000	Acquired		Common Stock (108000)	Direct

Footnotes

F1: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant.